Pfizer Limited — Important, 31-01-2025: Financial Result Updates

Pfizer Limited's consolidated financials for the quarter and nine months ended December 31, 2024, reveal total revenues of ₹575.82 crore, reflecting a growth of 7.69% year-over-year compared to ₹534.16 crore in the previous period. This growth appears driven by operational improvements and an increase in demand for pharmaceutical products.

The company reported a net profit of ₹167.99 crore, compared to ₹175.94 crore in the same period last year, indicating a slight decrease attributed to higher costs associated with employee benefits and other operational expenses. The Earnings Per Share (EPS) for the period stands at ₹3.67, down from ₹3.85 previously.

Operational costs have increased by 0.9%, primarily due to an uptick in employee expenses and depreciation costs. However, the company has managed to maintain a solid cost structure, which reflects effective cost management strategies amidst rising industry expenses.

On the balance sheet, total assets are stable, with an emphasis on cash flow management that remains robust, ensuring liquidity for future operational requirements. This positions Pfizer well for continuing investments and potential strategic expansions.

Overall, Pfizer's strategic focus on managing costs while enhancing operational efficiencies is commendable. Given the slight decline in profits but stable revenue growth, retail investors might consider maintaining their current positions.